d'Ettorre et al., Frontiers in Medicine,
doi:10.3389/fmed.2020.00389 (Peer Reviewed)
Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19
Retrospective 70 hospitalized patients in Italy, 28 treated with probiotic Sivomixx, showing lower risk of respiratory failure and faster recovery with treatment.
d'Ettorre et al., 7/7/2020, retrospective, Italy, Europe, peer-reviewed, 17 authors.
risk of death, 87.0% lower, RR 0.13, p = 0.14, treatment 0 of 28 (0.0%), control 4 of 42 (9.5%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of mechanical ventilation, 76.9% lower, RR 0.23, p = 0.51, treatment 0 of 28 (0.0%), control 2 of 42 (4.8%), continuity correction due to zero event (with reciprocal of the contrasting arm).
respiratory failure, 88.4% lower, RR 0.12, p = 0.01, treatment 28, control 42, RR approximated with OR.
Effect extraction follows
pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.